In support of this, these authors showed that an acute treatment with a PPARβ/δ agonist GW501516 depletes WAT lipid accumulation in these genetically obese mice, suggesting that the anti-obesity actions of PPARβ/δ are not dependent on leptin signaling pathways [25]. Here, PPARD is linked to obesity disorder.